Design and analysis of a stiffened composite fuselage panel

The design and analysis of stiffened composite panel that is representative of the fuselage structure of existing wide bodied aircraft is discussed. The panel is a minimum weight design, based on the current level of technology and realistic loads and criteria. Several different stiffener configurations were investigated in the optimization process. The final configuration is an all graphite/epoxy J-stiffened design in which the skin between adjacent stiffeners is permitted to buckle under design loads. Fail safe concepts typically employed in metallic fuselage structure have been incorporated in the design. A conservative approach has been used with regard to structural details such as skin/frame and stringer/frame attachments and other areas where sufficient design data was not available

Sizing-stiffened composite panels loaded in the postbuckling range

Stiffened panels are widely used in aircraft structures such as wing covers, fuselages, control surfaces, spar webs, bulkheads, and floors. The detailed sizing of minimum-weight stiffened panels involves many considerations. Use of composite materials introduces additional complexities. Many potential modes of failure exist. Analyses for these modes are often not trivial, especially for those involving large out-of-plane displacements. Accurate analyses of all potential failure modes are essential. Numerous practical constraints arise from manufacturing/cost considerations and from damage tolerance, durability, and stiffness requirements. The number of design variables can be large when lamina thicknesses and stacking sequence are being optimized. A significant burden is placed on the sizing code due to the complex analyses, practical constraints, and number of design variables. On the other hand, sizing weight-efficient panels without the aid of an automated procedure is almost out of the question. The sizing code postbuckled Open-Stiffener Optimum Panels (POSTOP) has been developed to aid in the design of minimum-weight panels subject to the considerations mentioned above. Developed for postbuckled composite panels, POSTOP may be used for buckling resistant panels and metallic panels as well. The COPES/CONMIN optimizer is used in POSTOP although other options such as those in the ADS system could be substituted with relative ease. The basic elements of POSTOP are shown. Some of these elements and usage of the program are described

The effect of flight line spacing on radioactivity inventory and spatial feature characteristics of airborne gamma-ray spectrometry data

Airborne Gamma Spectrometry (AGS) is well suited to the mapping of radioactivity in the environment. Flight parameters (e.g. speed and line spacing) directly affect the rate of area coverage, cost, and data quality of any survey. The influences of line spacing have been investigated for data from inter‐tidal, coastal and upland environments with a range of <sup>137</sup>Cs activity concentrations and depositional histories. Estimates of the integrated <sup>137</sup>Cs activity (‘inventory’) within specified areas and the shapes of depositional features were calculated for subsets of the data at different line spacings. Features with dimensions greater than the line spacing show variations in inventory and area of less than 3%, and features with dimensions less than the line spacing show larger variations and a decreased probability of detection. The choice of line spacing for a task is dependent on the dimensions of the features of interest and required edge definition. Options for line spacing for different tasks are suggested. It is noted that for regional mapping, even 5–10 km line spacing can produce useful data

POSTOP: Postbuckled open-stiffener optimum panels, user's manual

The computer program POSTOP developed to serve as an aid in the analysis and sizing of stiffened composite panels that may be loaded in the postbuckling regime, is intended for the preliminary design of metal or composite panels with open-section stiffeners, subjected to multiple combined biaxial compression (or tension), shear and normal pressure load cases. Longitudinal compression, however, is assumed to be the dominant loading. Temperature, initial bow eccentricity and load eccentricity effects are included. The panel geometry is assumed to be repetitive over several bays in the longitudinal (stiffener) direction as well as in the transverse direction. Analytical routines are included to compute panel stiffnesses, strains, local and panel buckling loads, and skin/stiffener interface stresses. The resulting program is applicable to stiffened panels as commonly used in fuselage, wing, or empennage structures. The capabilities and limitations of the code are described. Instructions required to use the program and several example problems are included

Jump-like unravelings for non-Markovian open quantum systems

Non-Markovian evolution of an open quantum system can be `unraveled' into pure state trajectories generated by a non-Markovian stochastic (diffusive) Schr\"odinger equation, as introduced by Di\'osi, Gisin, and Strunz. Recently we have shown that such equations can be derived using the modal (hidden variable) interpretation of quantum mechanics. In this paper we generalize this theory to treat jump-like unravelings. To illustrate the jump-like behavior we consider a simple system: A classically driven (at Rabi frequency $\Omega$) two-level atom coupled linearly to a three mode optical bath, with a central frequency equal to the frequency of the atom, $\omega_0$, and the two side bands have frequencies $\omega_0\pm\Omega$. In the large $\Omega$ limit we observed that the jump-like behavior is similar to that observed in this system with a Markovian (broad band) bath. This is expected as in the Markovian limit the fluorescence spectrum for a strongly driven two level atom takes the form of a Mollow triplet. However the length of time for which the Markovian-like behaviour persists depends upon {\em which} jump-like unraveling is used.Comment: 11 pages, 5 figure

Functional rescue of dystrophin deficiency in mice caused by frameshift mutations using Campylobacter jejuni Cas9

Duchenne muscular dystrophy (DMD) is a fatal, X-linked muscle wasting disease caused by mutations in the DMD gene. In 51% of DMD cases, a reading frame is disrupted because of deletion of several exons. Here, we show that CjCas9 derived from Campylobacter jejuni can be used as a gene editing tool to correct an out-of-frame Dmd exon in Dmd knockout mice. Herein, we used Cas9 derived from S. pyogenes to generate Dmd knockout (KO) mice with a frameshift mutation in Dmd gene. Then, we expressed CjCas9, its single-guide RNA, and the eGFP gene in the tibialis anterior muscle of the Dmd KO mice using an all-in-one adeno-associated virus (AAV) vector. CjCas9 cleaved the target site in the Dmd gene efficiently in vivo and induced small insertions or deletions at the target site. This treatment resulted in conversion of the disrupted Dmd reading frame from out-of-frame to in-frame, leading to the expression of dystrophin in the sarcolemma. Importantly, muscle strength was enhanced in the CjCas9-treated muscles, without off-target mutations, indicating high efficiency and specificity of CjCas9. This work suggests that in vivo DMD frame correction, mediated by CjCas9 has great potential for the treatment of DMD and other neuromuscular diseases

Consistent Quantum Counterfactuals

An analysis using classical stochastic processes is used to construct a consistent system of quantum counterfactual reasoning. When applied to a counterfactual version of Hardy's paradox, it shows that the probabilistic character of quantum reasoning together with the ``one framework'' rule prevents a logical contradiction, and there is no evidence for any mysterious nonlocal influences. Counterfactual reasoning can support a realistic interpretation of standard quantum theory (measurements reveal what is actually there) under appropriate circumstances.Comment: Minor modifications to make it agree with published version. Latex 8 pages, 2 figure

Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II.

Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading to pain, stiffness, physical dysfunction, and short stature. Tumor necrosis factor - alpha (TNF-α) is elevated in individuals with MPS I and II and associated with pain and physical dysfunction. Therefore, we evaluated the safety and effects of the TNF-α inhibitor adalimumab in patients with MPS I and II in a 32-week, randomized, double blind, placebo-controlled, crossover study of adalimumab at a dose of 20 mg (weight 15-<30 kg) or 40 mg (weight ≥ 30 kg) administered subcutaneously every other week or saline placebo for 16 weeks. Participants were evaluated at baseline, week 16, and week 32 with the Children's Health Questionnaire - Parent Form 50 (CHQ-PF50), the Pediatric Pain Questionnaire (PPQ), range-of-motion (ROM) measurements, anthropometry, six-minute walk test (6MWT), hand dynamometer, and laboratory evaluations for safety. The primary outcome was safety and primary efficacy outcome was bodily pain (BP) measured by the CHQ-PF50. Two subjects, one with MPS I and one with MPS II, completed the study. Adalimumab was well tolerated and there were no serious adverse events. Standardized BP scores for age and gender were higher (i.e. less pain) at the end of the treatment versus placebo phase for both subjects. Subject #1 became unblinded during treatment due to skin erythema. Behavior measured by both CHQ-PF50 and parental report improved during treatment compared to placebo in both subjects. ROM improved by > 5° in seven of eight joints in Subject #1 and five of eight joints in Subject #2 (range 7.0° to 52.8°). There was no change in the PPQ, 6MWT, or hand dynamometer. Data from this small pilot study suggest that treatment with adalimumab is safe, tolerable, and may improve ROM, physical function, and possibly pain, in children with MPS I or II. However, additional clinical trials are needed before this therapy should be recommended as part of clinical care